Vitamin D interacts with Esr1 and Igf1 to regulate molecular pathways relevant to Alzheimer’s disease by Landel, Véréna et al.
Vitamin D interacts with Esr1 and Igf1 to regulate
molecular pathways relevant to Alzheimer’s disease
Ve´re´na Landel, Pascal Millet, Ke´vin Baranger, Be´atrice Loriod, Franc¸ois
Fe´ron
To cite this version:
Ve´re´na Landel, Pascal Millet, Ke´vin Baranger, Be´atrice Loriod, Franc¸ois Fe´ron. Vitamin D
interacts with Esr1 and Igf1 to regulate molecular pathways relevant to Alzheimer’s disease.




Submitted on 27 May 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
RESEARCH ARTICLE Open Access
Vitamin D interacts with Esr1 and Igf1 to
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Abstract
Background: Increasing evidence suggests a potential therapeutic benefit of vitamin D supplementation against
Alzheimer’s disease (AD). Although studies have shown improvements in cognitive performance and decreases in
markers of the pathology after chronic treatment, the mechanisms by which vitamin D acts on brain cells are
multiple and remain to be thoroughly studied. We analyzed the molecular changes observed after 5 months of
vitamin D3 supplementation in the brains of transgenic 5xFAD (Tg) mice, a recognized mouse model of AD, and
their wild type (Wt) littermates. We first performed a kinematic behavioural examination at 4, 6 and 8 months of
age (M4, M6 and M8) followed by a histologic assessment of AD markers. We then performed a comparative
transcriptomic analysis of mRNA regulation in the neocortex and hippocampus of 9 months old (M9) female mice.
Results: Transcriptomic analysis of the hippocampus and neocortex of both Wt and Tg mice at M9, following 5 months
of vitamin D3 treatment, reveals a large panel of dysregulated pathways related to i) immune and inflammatory
response, ii) neurotransmitter activity, iii) endothelial and vascular processes and iv) hormonal alterations. The
differentially expressed genes are not all direct targets of the vitamin D-VDR pathway and it appears that vitamin
D action engages in the crosstalk with estrogen and insulin signaling. The misexpression of the large number of
genes observed in this study translates into improved learning and memory performance and a decrease in
amyloid plaques and astrogliosis in Tg animals.
Conclusions: This study underlies the multiplicity of action of this potent neurosteroid in an aging and AD-like
brain. The classical and non-classical actions of vitamin D3 can act in an additive and possibly synergistic manner
to induce neuroprotective activities in a context-specific way.
Keywords: Vitamin D, Alzheimer’s disease, Transcriptome, Nervous system, Inflammatory response, Hormonal activity
Background
The world is currently facing a global Alzheimer’s disease
(AD) pandemic and there is an urgent necessity to find
drugs that can halt, or even better, cure this pathology.
Clinicians and researchers are actively looking for mole-
cules with neuro-protective, regenerative and immuno-
modulatory properties [1]. Preferably, to speed up their
delivery to AD patients, the selected compounds should
be FDA-approved with a well-known toxicity range.
With the intention of unveiling new molecular candi-
dates, we elected a recognized animal model for this
disease, namely the 5XFAD transgenic mice [2], that ex-
hibit mnesic deficits, increased Amyloid Precursor Protein
(APP) processing and an early onset for inflammation and
plaque formation [3]. We timely assessed gene misexpres-
sion in the hippocampus and neocortex of 5XFAD female
mice at presymptomatic, prodromal-like and symptomatic
stages of the pathology. As expected, we observed a
dysregulated expression of genes involved in inflamma-
tion, NADPH oxidase complex, phagocytic processes
and interferon-γ-related pathways [4]. Remarkably, we
also found a modulated expression of 784 vitamin D-
associated transcripts (Additional file 1).
Vitamin D3 is a fat-soluble and seco-steroid hormone.
Unlike other vitamins, vitamin D3 is mainly produced
after adequate exposure to sunlight. Where this exposure
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is lacking, dietary intake of vitamin D (vitamin D2 or
vitamin D3) is required. The epidermis contains a chol-
esterol metabolite that under ultraviolet light produces
a precursor, previtamin D3. After isomerization and
two separate hydroxylations, the active 1,25-dihydroxy-
vitamin D3 (1,25(OH)2D3 or calcitriol) is produced.
1,25(OH)2D3 operates via both nuclear receptors named
Vitamin D Receptor (VDR) (part of the superfamily of ster-
oid hormone receptors) and non-genomic systems. The
1,25(OH)2D3/VDR complex interacts with specific gen-
omic sequences named Vitamin D Responsive Elements
(VDRE) found in promoter regions and has been shown to
regulate the transcription of a large number (up to 1000)
of target genes [5, 6].
Epidemiological and clinical data have shown that i)
high serum levels of 25-hydroxyvitamin D (25(OH)D) as-
sociate with better cognitive test performance [7, 8] and ii)
vitamin D deficiency is found in patients with Alzheimer’s
disease [9–13]. Other studies reported i) associations be-
tween VDR polymorphisms and cognitive function in Alz-
heimer’s disease patients [14–19] and ii) decreased VDR
mRNA levels in the hippocampus of AD patients [20].
1,25(OH)2D3 has also been shown to i) enhance cere-
bral clearance of human Amyloid Beta (Aβ) peptide
from mouse brain across the blood–brain barrier [21],
ii) prevent Aβ-induced alterations in cortical neurons
through upregulation of the VDR and downregulation
of L-type voltage sensitive calcium channels [22, 23].
Experimental observations confirmed that i) vitamin D
deficiency increases spatial learning deficits in a rat
model of AD [24] likely by enhancing Aβ deposition
through modulation of amyloid processing [25] and ii)
vitamin D3 supplementation decreases pathological
markers of the disease, such as Aβ deposition, in a
transgenic mouse model [26]. However, relatively little
is known about the mechanisms of action of this ster-
oid hormone in demented brains.
Purposely, we assessed the therapeutic benefit of vitamin
D3 in 5XFAD mice, supplemented after the onset of the
symptoms, from month 4 (M4) to month 9 (M9). Along
the course of the disease, we measured memory abilities
and, at the end of the experiment, we quantified amyloid
plaque load. In addition, using pangenomic cDNA micro-
arrays and bioinformatic tools, we identified the genes that
were regulated, directly or indirectly, by a vitamin D3 inter-
vention. This study is the first to provide insight into the
molecular mechanisms at play after chronic treatment with
vitamin D3 in both healthy aging and AD-like brains.
Results
Vitamin D3 supplementation induces an extensive gene
dysregulation
To reveal the potential molecular targets of vitamin D3
in specific brain regions, we conducted a series of
transcriptomic experiments. The study allowed a com-
parison of dysregulated genes and associated molecular
pathways affected by vitamin D3 supplementation in
both a non-AD and AD context, i.e. Wild-type (Wt)
versus Transgenic (Tg) animals. Figure 1 reveals the
total number of transcripts affected in Wt or Tg ani-
mals after 5 months of vitamin D3 supplementation. A
total of 2211 genes are dysregulated in Wt animals in
both the hippocampus and cortex combined, compared
to a total of 1277 Differentially Expressed Genes
(DEGs) in Tg mice after vitamin D3 treatment (Fig. 1a).
Vitamin D3 supplementation induces a dysregulation of
nearly twice as many genes in Wt animals as compared
to Tg. Details about these DEGs are given in Additional
file 2. There is no significant difference in terms of the
number of upregulated or downregulated genes in both
genotypes and brain regions (Fig. 1a). When consider-
ing each brain area analyzed, there is little difference in
the number of dysregulated genes for a given genotype
(Fig. 1b). In Wt mice, about 10 % of DEGs are common
to both tissues while 13 % shared DEGs can be ob-
served in Tg animals (Fig. 1b). Interestingly, a number
of DEGs are common to both genotypes in both brain
areas (Fig. 1c). Up to 366 genes are commonly dysregu-
lated after vitamin D3 treatment in both Wt and Tg
mice (Fig. 1d). Using Ingenuity Pathway Analysis (IPA)
software, the clustering of the 366 genes indicates that
among the top canonical pathways, the ones displaying
the largest number of DEGs are: Axon guidance signaling
(13 genes), Protein kinase A signaling (13), ILK signaling
(9), Huntington’s disease signaling (9), Glioblastoma
Multiform signaling (8), Cdc42 signaling (8), IL8 signaling
(8), Agranulocyte adhesion and diapedesis (8), Tight junc-
tion signaling (7), Embryonic stem cell pluripotency (6),
Corticotropin Releasing Hormone signaling (6), Commu-
nication between innate and adaptive immune cells (5),
Glutamate receptor signaling (5) and Dopamine receptor
signaling (5). Furthermore, 39 out of 366 genes are associ-
ated to inflammatory response, 26 to cognition and 25 to
Alzheimer’s disease (Fig. 1e).
An intriguing expression of hormone transcripts in the
cortex and hippocampus
One of the aims of this transcriptomic analysis was to
extract information about genes whose expression is
modified in the nervous system after 5 months of vita-
min D3 supplementation, regardless of the pathological
context. One way to obtain such information is to refine
the working dataset to include only genes that are com-
monly dysregulated in all tested conditions. Table 1
shows the list of genes found to be dysregulated in Wt
and Tg mice, in both the hippocampus and cortex. In
these four conditions, we found 28 DEGs, with varying
fold changes according to the genotype and brain region
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studied, that are consistently regulated after 5 months of
vitamin D3 supplementation. To gain better sense of the
biological functions represented by the differentially
expressed genes, we performed a Functional Annotation
Clustering using the NIH David tool. This analysis
revealed that the genes in this dataset are related to five
different biological clusters: regulation of phosphoryl-
ation, hormone activity, membrane trafficking, nucleo-
tide binding and metal ion binding. A less restrictive
additional analysis was performed on DEGs found in at
Fig. 1 Schematic overview of gene expression in cortex and hippocampus of 9 month-old wild type and transgenic mice reveals that a 5 month
vitamin D3 supplementation induces an extensive transcript dysregulation. a Graphical representation of the number of upregulated (dark grey)
and downregulated (light grey) DEGs in either the hippocampus, cortex or combined regions in both Wt and Tg animals having been fed a vitamin D3
diet for 5 months. The number of genes specifically dysregulated in wild type mice is twice as large as in transgenic mice. b-c Venn diagrams indicating
the number of overlapping (grey) and non overlapping DEGs when the two brain areas are compared in wild type and transgenic mice (b) and when
the two strains are compared at the hippocampal or cortex level (c). d Venn diagram showing that, when hippocampal and cortical data are combined,
vitamin D3 supplementation triggers the dysregulation of 366 genes in both strains. e List and top associated biological functions of the 366 DEGs
common to both strains. Overall, 39 are associated to inflammatory response, 26 to cognition and 25 to Alzheimer’s disease. Fold change (FC) cutoff
used for above analyses was -1.5> FC <1.5
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least three out of the four conditions. Table 2 represents
the top ten biological clusters associated with this data-
set. One hundred thirty-six genes were differentially
expressed (Additional file 3) and when performing func-
tional annotation clustering of these DEGs, the number
one biological function is hormone activity (Table 2).
Eight genes fall into this ontological category: Avp, Igf1,
Igf2, Nppa, Oxt, Pmch, Prl, Trh. Bearing in mind that
several of these neuropeptides are largely found in the
pituitary axis, it is extremely intriguing to find them dif-
ferentially expressed in the cortex or hippocampus of
5XFAD mice.
Among the top ten biological pathways affected by
vitamin D3 treatment, two of them concern synaptic
processes and neurotransmission with dysregulation of
genes such as Syn3, Syt10 and Sv2c, while two others are
related to immune responses including genes such as
C1qb, Cd4 and Cd74 (Table 2). A literature search was
then performed to determine whether some of these
genes contain a putative VDRE in their sequence.
Among the 136 genes commonly dysregulated, only four,
Fos, Gcnt1, Irak2, St6galnac1, were found to present a
known functional VDRE in their promoter region [6].
The effects of vitamin D3 supplementation vary
according to the health status of the animal
To move further and comprehensively assess the effect
of vitamin D on brain functioning, we analyzed the
Table 1 List of commonly dysregulated genes in the cortex and hippocampus of transgenic and wild type mice
Fold change
Hipocampus Cortex
Gene symbol Entrez gene name WtVitD/Wt TgVitD/Tg WtVitD/Wt TgVitD/Tg
Ahcy adenosylhomocysteinase −1,73 −2,07 1,79 2,07
Atg4c autophagy related 4C, cysteine peptidase −2,72 −2,75 4,49 4,82
Avp arginine vasopressin −1,59 2,21 1,73 3,96
C130078n14 uncharacterized protein C130078N14 −2,13 −2,17 3,92 2,77
Cdk5rap1 CDK5 regulatory subunit associated protein 1 −1,78 −2,14 2,66 2,92
Cpne1 copine I −1,56 −1,82 1,6 1,71
Dnajb8 DnaJ (Hsp40) homolog, subfamily B, member 8 −1,85 1,98 −1,92 −1,73
Fam205a family with sequence similarity 205, member A 2,34 2,78 1,61 −1,55
Fkbp1a FK506 binding protein 1A, 12kDa 1,97 1,62 −1,72 −1,52
Gbp6 guanylate binding protein family, member 6 2,19 2,21 −2,65 −3,23
Gm4924 predicted gene 4924 1,68 1,94 2,14 1,53
Hla-drb5 major histocompatibility complex, class II, DR beta 5 1,86 1,53 −2,53 −2,34
Iqcf4 IQ motif containing F4 2,74 2,22 −1,54 −1,73
Iqsec3 IQ motif and Sec7 domain 3 −5,23 4,49 −3,3 1,58
Kcnj6 potassium channel, inwardly rectifying subfamily J, member 6 1,61 1,93 −1,79 −1,67
Kdr kinase insert domain receptor −1,6 1,68 1,53 −1,64
Mirg miRNA containing gene −1,91 1,88 −3,41 −1,68
Nanog Nanog homeobox −2,91 1,53 −1,52 −1,66
Ocel1 occludin/ELL domain containing 1 −3,07 −3,98 3,52 3,21
Omp olfactory marker protein −1,54 −10,41 3,18 1,66
Oxt oxytocin/neurophysin I prepropeptide −2,75 4,04 2,03 4,74
Ppp1r16b protein phosphatase 1, regulatory subunit 16B 2,29 2,39 −1,78 −1,78
Prkcd protein kinase C, delta −2,18 −2,52 1,84 1,65
Prl prolactin 1,93 −1,88 10,07 10,54
Rnase4 ribonuclease, RNase A family, 4 1,61 2,12 −2,14 −2,07
Sdc4 syndecan 4 2,38 1,95 −1,91 −1,81
Serpina3g serine (or cysteine) peptidase inhibitor, clade A, member 3G 2,78 1,94 −1,8 −2,42
Znf669 zinc finger protein 669 −2,08 −1,9 1,84 2,2
Dysregulated transcripts in the hippocampus and cortex of vitamin D3 supplemented wild type and transgenic mice in comparison with unsupplemented
littermates. The gene symbol, the full name and the fold change of each gene are indicated
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record of dysregulated genes, in accordance with their
role in well-described metabolic pathways. For each
strain, we combined transcriptomic data from the hippo-
campus and the neocortex at M9 and, using Ingenuity
software, we listed the main canonical pathways that
were modified by the vitamin D3-enriched diet. We then
compared the two strains of animals (Wt vs Tg). All per-
turbed pathways and the names of their associated DEGs
are recorded in Additional file 4. Out of the 90 major
modified canonical pathways, 42 were common to both
strains. As shown in Fig. 2, 16 of them are related to ei-
ther the nervous or the immune system.
In regard to the brain (Fig. 2a), the largest number of
dysregulated genes – 53 and 38 for the Wt and Tg ani-
mals, respectively – is associated to Axon guidance sig-
naling. Within both strains, we observe a modified
expression of growth factors (e.g. Bdnf, Bmp1, Bmp6,
Egf, Igf1, Figf, Ntf3, Vegfc), chemo-attractive/repulsive
agents (e.g. Sema3b, Sema3c, Sema4g, Sema6b, Sema6c),
proteases (e.g. Ace, Adam11, Adamts2, Adamts8, Adamts9,
Mmp9) and TGF/WNT/β-catenin-associated molecules
(e.g. Tgfb1, Tgfbr1, Tgfbr2, Wnt1, Wnt3, Wnt6, Wnt9a,
Wnt9b, Wnt16). Two other metabolic pathways - the sig-
naling of the corticotropin releasing hormone and the
multiform glioblastoma – include large subsets of dys-
regulated genes. However, the highest ratio (number of
dysregulated genes/number of genes involved in the
pathway) is found for the neuroprotective role of
THOP1 in Alzheimer’s disease.
With respect to the immune system (Fig. 2b), three
canonical pathways – Role of macrophages, fibroblasts
and endothelial cells in rheumatoid arthritis, Agranulo-
cyte adhesion and diapedesis and Dendritic cell matur-
ation - emerge as primarily affected by vitamin D3
supplementation, in both strains. Other modified meta-
bolic pathways include Communication between innate
and adaptive immune cells, Complement system and
MIF regulation of innate immunity. Nonetheless, the
peak ratios are observed for the Role of Il17F in inflam-
matory diseases and the role of Il17A in psoriasis.
In addition to this strain independent response to vita-
min D3 supplementation, the brains display specific
modifications in line with the health status of the ani-
mal. For example, vitamin D3-enriched diet modify the
expression of glucocorticoid and glutamate receptors in
wild type animals and GABA, dopamine and serotonin
receptors in transgenic animals (Fig. 2a). Similarly, vita-
min D3 alters interleukin signaling in a strain-dependent
manner. IL-12 and IL-8 pathways are adjusted in Wt
and Tg brains, respectively (Fig. 2b). Other examples of
discrepancies can be listed. The non pathological brain
responds to vitamin D3 treatment by modifying the
expression of i) nitric oxide in macrophages, ii) neuro-
trophins and iii) molecules related to Huntington disease
whereas the pathological brain reacts by altering the
expression of iv) nitric oxide in endothelial cells, v)
cathecholamines and vi) molecules associated to Mul-
tiple Sclerosis.
Vitamin D3, a potent upstream regulator altering the
expression of Alzheimer’s disease-associated genes
To further decipher the detailed role of vitamin D in
brain functioning, we narrowed our analysis to the genes
that are directly or indirectly regulated by vitamin D or
its related-metabolites. Using Ingenuity software, we
listed all dysregulated molecules whose expression has
been associated, in the literature, to this steroid.
As summarized in Fig. 3, we observed 290 and 249
vitamin D-related DEGs respectively, when comparing
vitamin D3-supplemented Wt and Tg mice with their
unsupplemented littermates. Within these two pools,
188 and 151 genes are part of the initial list of 784 vita-
min D-associated transcripts whose expression is altered
in the brain of transgenic animals (Additional file 5).
Table 2 Top ten biological clusters associated with transcripts dysregulated in at least 3 out of 4 conditions: misexpression in the
hippocampus and/or cortex of transgenic and/or wild type mice
Annotation term Number of genes Genes
Hormone activity 8 Avp, Igf1, Igf2, Nppa, Oxt, Pmch, Prl, Trh
Synaptic vesicle 5 Doc2g, Slc17a6, Syn3, Sv2c, Syt10
Regulation of phosphorylation 6 Cd4, Cd74, Cdk5rap1, Fkbp1a, Irak2, Prkcd
Membrane-bounded vesicle 8 Capn11, Doc2g, Gpnmb, Prl, Slc17a6, Syn3, Sv2c, Syt10
Striated muscle tissue development 4 Fkbp1a, Foxp1, Rxrg, Tnnt2
Blood circulation 4 Acta2, Ace, Avp, Nppa
Lymphocyte activation 4 Cd4, Cd74, Fkbp1a, Foxp1
C2 calcium-dependent membrane targeting 4 Cpne1, Doc2g, Prkcd, Syt10
Immune effector process 4 Cd74, C1qb, Foxp1, Prkcd
Synapse 5 Shc4, Slc17a6, Syn3, Sv2c, Syt10
Cluster name, number of genes within each cluster and acronym of each gene are indicated
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Furthermore, when assessing the presence of a VDRE in
the promoter region of these DEGs [6], we found 25 (13 %)
and 18 (12 %) transcripts in the two above-mentioned pop-
ulations (highlighted in grey in Additional file 5). As a
comparison, 68 (9 %) out of the 784 genes listed in
Additional file 1 harbor a VDRE. We then clustered the
two populations of vitamin D-related DEGs and, as shown
on Fig. 3, we highlighted three sub-populations, composed
of transcripts involved in inflammatory response, Alzhei-
mer’s disease and cognition.
At this point, we decided to validate the observed ex-
pression of certain DEGs of our dataset, using quantita-
tive PCR (qPCR). We chose two hormones, Oxt and
Avp, which are, according to the microarray results,
dysregulated in the hippocampus and cortex of both Wt
and Tg animals. We also focused on four vitamin D-
related genes involved in AD commonly dysregulated in
the neocortex and hippocampus of Tg animals, namely
Lcn2, Ptgs2, Esr1 and Igf1. An overexpression of the
transcripts Oxt and Avp is confirmed in the cortex as
well as an upregulation of Esr1 in the hippocampus. The
gene coding for Lcn2 is overexpressed in both the hippo-
campus and the cortex. However, the downregulation of
Igf1 is not confirmed by qPCR analysis (Fig. 3b).
Vitamin D3 supplementation alters the expression of
many Alzheimer’s disease-associated genes, even in Wt
brains. However, major differences can be observed. As re-
ported on Fig. 4, 29 and 27 transcripts are uniquely misex-
pressed in Wt and Tg animals, respectively. In addition,
13 out of the 16 vitamin D-related DEGs emerging at the
intersection of both strains are inversely expressed. The
three transcripts that are similarly misexpressed are Ace,
Igf1 and Gfap, strongly related to Alzheimer’s disease. All
three are underexpressed when compared to unsupple-
mented animals (Fig. 4).
The consequences of this discordant response to vita-
min D3 treatment are unknown since the Wt mice dis-
play no AD symptoms and features. Nevertheless, it
allowed us to envision the putative mechanism of action
of vitamin D3 or its related metabolites (Fig. 4). Vitamin
D3 or 1,25(OH)2D3 and its receptor likely act via four
regulators, namely IGF1, ESR1, ERK and NF-κB. Igf1 is
underexpressed in both strains while Esr1 is overex-
pressed in Tg brains and underexpressed in Wt brains.
The expression of Erk and Nf-κb is unchanged in both
strains but many transcripts under their control are mis-
expressed in Tg and Wt animals. Downstream gene reg-
ulators include Fos, Stat1 and Stat3. The former is
overexpressed in Tg and underexpressed in Wt animals.
Vitamin D3 treatment impacts amyloid plaque load and
gliosis in transgenic animals
In order to examine whether a 5-month therapeutic
intervention with vitamin D3 translated into a positive
functional outcome, animals were analyzed at the histo-
logical and behavioral levels for known markers of AD
pathogenesis. At the histological level, vitamin D3 sup-
plementation decreased the quantity of plaques in three
different brain regions of Tg mice: frontal cortex, hippo-
campus and neocortex (Fig. 5a). Astrogliosis, assessed
through GFAP-immunostaining, is greatly increased in
Tg animals compared to Wt. Vitamin D3 treatment of
Tg animals during 5 months significantly decreases
GFAP reactivity. However, this significant decrease is
only observed in the frontal cortex (Fig. 5b). Microglial
activation was assessed through immunostaining with
IBA1 antibody and although there is an increase in this
microglial marker between Wt and Tg control mice,
vitamin D3 supplementation increases IBA1 immunore-
activity only in the frontal cortex of Tg animals when
compared to their unsupplemented littermates (Fig. 5c).
Four months of vitamin D3-enriched diet is sufficient to
rescue cognitive deficits in the 5XFAD model
After 4 months of vitamin D3-supplemented diet, cogni-
tive performance was evaluated using two different para-
digms: the Y-maze and the 6-radial arm water maze. A
longitudinal study was first performed from M4 to M8
using the Y-maze. This study shows that Tg animals
display a decreased percent of alternation with time
whereas aging Tg animals on a high vitamin D3 diet do
not show any cognitive decline between M4 and M8
(Fig. 5d). At M8, we observed a significant decrease in
percent alternation performance in Tg mice. This effect
is rescued by treatment with vitamin D3 during 4 months
with no significant difference in the number of arms
entered (Fig. 5e and f). However, a high vitamin D3 diet
does not improve working memory in wild-type animals,
even at M8 (Fig. 5e). The RAWM was used in addition
to the Y-maze to assess hippocampal-dependent spatial
working memory and reference memory. At the end of
the learning process (end of day 3), results show a sig-
nificant decrease in the total number of errors for Tg
animals having been fed a vitamin D3 supplemented diet
compared to Tg animals on a control diet (Fig. 5g).
Discussion
Despite growing evidence that vitamin D deficiency is a
risk factor for cognitive decline and possibly Alzheimer’s
disease, very few studies have investigated the effect of
vitamin D supplementation in AD mouse models. To
our knowledge, this is the first transcriptomic study to
assess the effect of long-term vitamin D3 supplementa-
tion in the nervous system of an AD mouse model. This
work allowed us to examine the effects of chronic vita-
min D3 treatment in both normal aging and AD-like
brains, at the transcriptomic, histological and behavioral
levels. We observed a very large number of dysregulated
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Fig. 2 (See legend on next page.)
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genes in both the pathological and non AD-like cortex
and hippocampus of these animals at M9. On the one
hand, our results point out that, although there are
nearly double the number of DEGs in Wt animals com-
pared to Tg, a high number of genes misexpressed after
vitamin D3 supplementation are common to both geno-
types. On the other hand, when considering the bio-
logical pathways affected by these DEGs, the common
pathways between Wt and Tg often include different
subsets of genes for a given pathway or an inversed ex-
pression for the same gene. Our study underlines some
well-known actions of vitamin D and related metabolites,
namely its impact on immune and inflammatory processes
and cell cycle, along with previously shown effects on ner-
vous system molecules such as neurotrophins and nitric
oxide. However, our results also comprise unexpected
effects on the expression of hormonal transcripts and
reveal regulation of genes involved in synaptic func-
tion, axon guidance, endothelial and vascular pro-
cesses and stem cell pluripotency. A reassuring result
is that among the 784 genes predicted to be related
to vitamin D action in Tg animals, almost a third of
them are indeed regulated after 5 months of supple-
mentation. On top of that, the majority of the
Fig. 3 Analysis of vitamin D3-related dysregulated genes indicates an association with inflammatory response, Alzheimer’s disease and behavior.
a Overall, 290 and 249 vitamin D-related DEGs are found misexpressed when comparing vitamin D3-supplemented wild type and transgenic mice
with their unsupplemented littermates, respectively. Functional classification of these DEGs show importance of inflammatory, behavioural and
Alzheimer’s disease related processes. b qPCR validation of several dysregulated transcripts (n = 6 per group). An overexpression of the transcripts
oxytocin (Oxt) and arginine vasopressin (Avp) is confirmed in the cortex as well as an upregulation of estrogen receptor 1 (Esr1) in the hippocam-
pus. The gene coding for lipocalin 2 (Lcn2) is overexpressed in both the hippocampus and the cortex. * = p < 0.05
(See figure on previous page.)
Fig. 2 Top canonical metabolic pathways associated to gene dysregulation in the cortex and hippocampus of mice after 5 months of vitamin D3
supplementation: common versus strain-specific processes. Metabolic pathways associated to gene expression dysregulation were identified using
Ingenuity Pathway Analysis (IPA). Data from both the cortex and hippocampus were analyzed as one dataset and the main metabolic pathways
affected were clustered according to their association to the nervous (a) or the immune (b) system
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vitamin D-related genes are associated to Alzheimer’s
disease, in both the Wt and Tg brains. We show that
vitamin D action in the brain of this AD mouse
model likely involves signaling through ESR1 and
IGF1 and that a 5-month therapeutic intervention re-
duces the histological markers of the disease and re-
stores learning and memory capacities.
A common set of brain-associated genes regulated by
vitamin D
As mentioned earlier, no pangenomic study previously
assessed the effect of vitamin D3 supplementation in a
mouse model of Alzheimer’s disease. As a result, no
direct comparison can be performed. However, three
teams performed a thorough transcriptomic analysis on
Fig. 4 Schematic view of the putative mechanisms of vitamin D3 action in the brain. Vitamin D3 or its related metabolites and their receptors act
via four main regulators: IGF1, ESR1, ERK and NF-κB. Igf1 is underexpressed (green) in both strains while Esr1 is overexpressed in transgenic brains
and underexpressed in wild type brains (blue). The expression of Erk and NF-κB is unchanged in both strains but many transcripts under their control are
misexpressed in transgenic and wild type animals. Downstream gene regulators include Fos, Stat1 and Stat3. Fos is overexpressed in transgenic animals
and underexpressed in wild type animals (blue). Overall, 72 vitamin D-related transcripts are associated to either inflammation (19 genes) or
amyloidogenesis and amyloid plaques (29) or AD-related features (24). Sixteen genes are dysregulated in both strains (center areas). However,
only three of them - Ace, Igf1 and Gfap - are similarly misexpressed (black colour). Specific up- (red) and down-regulated (green) are indicated
for each strain
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i) brains from adult rats that were vitamin D-deprived
during gestation [27] ii) 1,25(OH)2D3-supplemented
cultures of neurons and glia [28] or pericytes [29] and
iii) hippocampus from middle aged rats after chronic
treatment with increasing doses of vitamin D3 [30]. A
cross examination of our data with those reported in
these studies reveals that the dysregulated expression of
46 genes – Aaas, Aldoa, Atp2b4, Bcam, Bmp1, C3, Cat,
Ccl2, Cntn4, Col16a1, Dpp6, Epas1, Fam120c, Fam70a,
Fbln1, Fkbp1a, Foxc1, Gfap, Grp, Hspa12a, Htr2c, Igf1,
Kdr, Kif1a, Lcat, Lpl, Ndst4, Nmbr, Nr4a2, Pde3b, Pmch,
Polr1b, Ppp2r2b, Rab33b, Sdc4, Senp7, Serinc2, Slc17a6,
Syt2, Thbd, Tia1, Trhr, Ttc39c, Vcam1, Vdr and Vps13c –
was formerly observed. The newly generated list may
appear relatively restricted when compared to our initial
dataset of 3488 dysregulated genes. However, given the
variety of scientific paradigms (depletion vs supplemen-
tation), the nature of the samples (cells vs different brain
regions), the molecular diversity of the administered
molecule (vitamin D3 vs 1,25(OH)2D3) and the hetero-
geneous size of the datasets, it is not of minor import-
ance to be able to establish an inventory of commonly
misexpressed genes in nervous cells or brain areas after
vitamin D3 treatment. Moreover, some studies have per-
formed targeted analysis of specific gene expression in
nervous system cells or tissues. For instance, Kaneko
and collaborators demonstrated that calcitriol regulates
the expression of two human brain-related genes con-
taining VDREs, tryptophan hydroxylase (Tph) and leptin
(Lep) [31]. These genes are also modulated in the brains
of either Wt or Tg mice in our study. In a set of experi-
ments examining the effect of maternal vitamin D defi-
ciency on fetal brain development, Hawes and colleagues
found that the pups from deficient mothers display a
modulated expression of Bdnf, Foxp2, Tgfb1 and Th,
which are also affected in certain conditions of our study
[32]. Altogether, these results underline the necessity for
additional work to be performed on the genomic effects of
vitamin D3 or 1,25(OH)2D3 in nervous system cells, as
there are clearly multiple targets relevant to brain function
and these could potentially explain a causal relationship
between vitamin D status and brain aging or AD.
We chose to perform a literature-based analysis of pos-
sible VDRE-containing DEGs in our datasets. To avoid
discrepancies between study designs, we initially based
our search on a large in silico and microarray-based study
by Wang and colleagues [6]. This revealed the presence of
a very limited number of putative VDREs in our dataset.
However, although ChiP-seq and genome-wide studies
have found that the most frequent sequence located in
VDR binding regions is the classic consensus VDRE motif,
these data also suggest the presence of other motifs whose
configuration diverge from the classic one and that might
or might not interact directly with the VDR [33].
Moreover, there appears to be 1000–10,000 possible chro-
matin VDR binding sites, according to the cell-type con-
sidered. In contrast the number of primary 1,25(OH)2D3
target genes is thought to be around 100–1000 per tissue,
suggesting that some genes are controlled by more than
one VDR binding site [33]. It is therefore difficult to con-
clude on the complete list of VDR direct targets in our
dataset. For instance, the study by Latimer and coworkers,
reported putative VDRE sequences in three genes from
our dataset – Cntn4, Ppp2r2b and Syt2 - which were not
previously identified by Wang and colleagues [6, 30].
These potential VDRE-containing DEGs are involved in
synaptic vesicle trafficking and neurotransmission, indi-
cating a possible direct modulation of these processes
by 1,25(OH)2D3 in the 5XFAD animal model. Since the
determination of true VDRE sequences would require
further investigation and that vitamin D metabolites are
also known to interact with various membrane-based
signaling pathways, the search for indirect actions, for
instance through modulation of immune processes, is
not to be excluded.
A confirmed immuno-modulatory role, several
mechanisms of action
The impact of vitamin D3 on inflammatory and immune
processes is all but unexpected since it is now well estab-
lished that vitamin D is a potent immune modulator [34].
1,25(0H)2D3 adjusts the expression of inflammatory cyto-
kines and prevents the proliferation of proinflammatory
cells [35]. As a general rule, 1,25(OH)2D3-treated T-cells
produce less proinflammatory Th1 (IL-2, interferon-γ,
tumor necrosis factor-α), Th9 (IL-9) and Th22 (IL-22)
cytokines and more anti-inflammatory Th2 (IL-3, IL-4, IL-
5, IL-10) cytokines [36–39]. In addition, Th17 activity is
affected by vitamin D. Activated T-cells treated with
1,25(OH)2D3 secrete reduced levels of IL-17, interferon-γ
and IL-21 [40]. The overall picture remains slightly blurry.
However, several key regulatory mechanisms begin to
surface.
Characteristically, when calcitriol binds the VDR/RXR,
the complex recognizes VDREs located in the promoter
region of target genes and activates or inhibits their
transcription. Concerning IL8 signaling, one of the top
commonly affected processes in both Wt and Tg animals
in our study, it is likely that IL8 is under the primary
control of 1,25(OH)D and VDR as a study recently dem-
onstrated the presence of VDR binding sites, in human
monocytes, within the interleukin 8 (IL8) cluster [41].
However, direct activation/repression of gene expression
is not the only mechanism by which the vitamin D sys-
tem can act on immune processes [42]. As presented in
Fig. 2, IL17A and IL17F signaling are affected by vitamin
D3 supplementation in both strains. No known VDREs
are present in the promoter regions of the TH17-
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signature cytokines that are Il17a and Il17f. Recently, it
was reported that vitamin D inhibition of Th17 differen-
tiation is obtained through modulation of Smads. More
specifically, the presence of a negative VDRE in Smad7
promoter leading to Smad7 repression along with a
VDR-dependent increase in Smad3 explain the changes
observed in Th17 cells during differentiation. In parallel,
1,25(OH)2D3 indirectly regulates the expression of
Fig. 5 Vitamin D3 supplementation reduces amyloid plaque load and cognitive deficits in transgenic animals. a In the three assessed brain
regions - frontal cortex, hippocampus and neocortex – the number of amyloid plaques is reduced in transgenic supplemented brains.
Vitamin D3 treatment limits astrogliosis (GFAP staining) in the frontal cortex and neocortex (b) and increases microglial activation (IBA1
staining) in the frontal cortex (c) of transgenic mice. Cognitive performance was assessed using the Y-maze and the radial arm water maze.
d Vitamin D3 supplemented transgenic mice do not display the decreased percent of alternation (Y maze) observed in unsupplemented
transgenic mice over time as measured at M4, M6 and M8. e, f At the end of the supplementation period (M8), a significant decrease in
percent alternation performance is observed in transgenic mice. This effect is rescued by vitamin D3 supplementation with no significant
difference in the number of arms entered. g Using the radial arm water maze, hippocampal-dependent spatial working memory was assessed. At the
end of the learning process (Day 3), a significantly reduced number of errors is observed in supplemented transgenic mice. * = p< 0.05; ** = p < 0.01
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Th17-specific genes Il17a and Il17f through activation of
ERK [43]. On top of direct transcriptomic action and in-
direct signaling through vitamin D receptors, it is also
possible that epigenetic mechanisms are also at play. For
example, 1,25(OH)2D3 regulates TLR-mediated inflam-
mation signaling by downregulating miR-155 in macro-
phages [44]. In our study, the modulated expression of
several members of the TLR family (Tlr1, Tlr2 and Tlr7),
with no known VDREs, could potentially involve such
mechanisms [45].
In addition to these various mechanisms, 1,25(OH)2D3
interacts with other transcription factors, such as the
glucocorticoid receptor, the nuclear factor of activated T-
cells (NFAT) or NF-κB resulting in overall decreased
inflammatory states [46]. It has been shown that, when ac-
tivated by its ligand, the VDR dimerizes with the gluco-
corticoid receptor and together they bind to glucocorticoid
responsive elements of genes, leading to an up-regulation
of anti-inflammatory molecules and a down-regulation of
pro-inflammatory genes [47]. Glucocorticoid receptor sig-
naling is one of the top biological functions affected in our
study, in both Wt and Tg brains. VDR is also able to bind
to an NFAT binding site, inducing a diminished NFAT
activity and downstream a repressed expression of IL-
2, cyclooxygenase 2 [48] and IL-17 [49]. Similarly,
1,25(OH)2D3 has been shown to inhibit NF-κB activa-
tion and signaling through up-regulation of IκB ex-
pression [50], interference with DNA binding [51] and
by enhancing FBW-7 dependent turnover of NF-κB
subunits [52], leading to a reduced production of pro-
inflammatory cytokines and pro-inflammatory enzymes
such as cyclooxygenase 2 [53]. Deciphering the exact
mode of action for 1,25(OH)2D3 modulation of immune
and inflammatory pathways, whether it involves direct
gene regulation, interactions and cross-talks between vari-
ous signaling pathways, and epigenetic mechanisms is be-
yond the scope of this study. However, it is clear that in
both the healthy and AD-like brain, vitamin D3 supple-
mentation induces a strong effect on inflammatory and
immune processes.
A background-specific action of vitamin D3
As established during the last 25 years, vitamin D and
its metabolites play crucial roles in cell proliferation
and differentiation, neuroprotection, neurotransmission
and neuroplasticity [54]. However, as observed in the
immune system, vitamin D3 action is space- and time-
specific. For example, a hypervitaminosis D alters the
synthesis of calcium binding proteins in the caudate/
putamen but not in the hippocampus and the cerebral
cortex [55]. Likewise, 3 weeks after the induction of an
experimental allergic encephalomyelitis, vitamin D3
supplementation provokes a massive downregulation of
inducible nitric oxide synthase (iNOS) only in the rat
cerebellum and brainstem [56]. The time window for
vitamin D depletion or supplementation can be essen-
tial as well. A transient developmental vitamin D defi-
ciency induces persistent morphological and molecular
changes in the adult rat brain [57–59] while an adult
vitamin D deficiency is associated with less profound
modifications [60].
An important finding from our transcriptomic analysis
is the effect of the pathological context on gene response
to vitamin D3 treatment. Indeed, our study provides evi-
dence that vitamin D3 has distinct genomic effects in a
non-pathologic and an AD-like brain. It is clear that,
when given to healthy animals, vitamin D3 induces dys-
regulation of genes implicated in an important number
of nervous system related pathways, whereas it appears
to act preferentially on immune system processes in Tg
mice, as illustrated in Fig. 2 and Additional file 4. When
considering nervous system related pathways, distinct
actions also appear. For instance, the non-pathologic
brain expresses genes associated to neurological func-
tions such as neurotrophins or tight junction modulation
while the pathologic brain activates/represses genes re-
lated to catecholamine synthesis or nitric oxide signaling
(Fig. 2). Another mean to demonstrate the effect of the
pathological background on gene dysregulation is to ob-
serve the subtle strain-associated changes in a common
canonical pathway. One of the most remarkable is the
Wnt/β-catenin signaling. Out of seven genes whose ex-
pression is dysregulated in both strains – Dsh, Frizzled,
Lef/Tgf, Lrp1, Rar, Tgfbr, Wnt – 5 are inversely misex-
pressed, indicating a putative opposite action of vitamin
D3. In addition, 12 and 7 genes are exclusively dysregu-
lated in the wild type and transgenic brains, respectively
(Additional file 6).
Several studies have highlighted the importance of vari-
ous factors, such as genetic settings, pathological back-
grounds, organ areas, cell subtypes, delivery time
windows, molecule concentrations, in determining the re-
sponse to vitamin D treatment. We can list a few exam-
ples. Conversely to cells from healthy individuals,
1,25(OH)2D3 increases the production of IL-2 in periph-
eral blood mononuclear cells from hemodialysis patients
[61]. 1,25(OH)2D3 addition in the culture medium of ei-
ther monocytes or macrophages induces an up-regulation
and a down-regulation of IL-1 and IL-6 mRNA, respect-
ively. These results were abolished or modified when cells,
before being stimulated with LPS or TNF-α, were pre-
incubated with 1,25(OH)2D3 [62]. 1,25(OH)2D3 triggers a
lessened expression of IL-10, followed by an increased
production, at a later stage [46].
Such regulation variability may explain some observed
discrepancies between the mouse strains used in the
current study. Genetically similar mice from the same
ages were fed with the same diet, during the same time
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window, and the same brain areas were analyzed. Yet, one
strain differs from the other by carrying two mutated hu-
man genes – APP and PSEN1 - that induce molecular,
morphological and behavioral changes. The 5XFAD mouse
model is an inflammatory model [4, 63] and, as mentioned
above, 1,25(OH)2D3 induces a different response when
acting on an inflamed tissue. Interestingly, this may even
apply to the canonical pathways that are dysregulated in
both strains (Additional file 4). In most if not all cases, the
two lists of misexpressed genes are not fully identical. This
confirms that the pleiotropic action of vitamin D3 and its
related metabolites strongly varies according to the health
status of the animal.
In addition, the strain-associated differences may be
related to the mechanism of action of vitamin D metab-
olites at play, whether it is a genomic response or the in-
duction of membrane based signaling pathways. In a
recent review, Michael Berridge develops the hypothesis
that vitamin D acts as a guardian of phenotypic stability
in a cell- and context-specific manner [64]. This stability
is maintained through modulation of various intracellu-
lar signaling pathways that are linked to vitamin D
action. For instance, vitamin D is capable of regulating
the expression of many components of pathways acti-
vated by insulin, TGFB1, WNT and NOTCH [65], whose
mRNA expression is affected in our study.
A strong link with Alzheimer’s disease in both Wt and Tg
The 5XFAD model is based on the insertion of two
human transgenes leading to a major increase of Aβ 1-
42 that accumulates rapidly in the brains of transgenic
animals. Overall, this model is both an inflammatory
and amyloidogenic model of Alzheimer’s disease [2, 4,
66]. As seen so far, the inflammatory component present
in Tg animals is highly addressed by vitamin D3 treat-
ment and, to a lesser extent, in Wt animals. Other ef-
fects of gene dysregulation in the brain of both Wt and
Tg mice relate to Alzheimer’s disease. For instance, one
of the commonly dysregulated pathways, described in
Additional file 4, concerns the neuroprotective role of
THOP1. THOP1, an oligopeptidase whose levels increase
upon Aβ exposure, is found overexpressed in human AD
brains, and appears to engage in neuroprotective activities
against toxic effects of Aβ at early stages of the disease
[67]. This pathway is significantly affected in our study,
however it is difficult to conclude about the outcome in-
duced by such dysregulation at the functional level, espe-
cially since the expression of different genes in the
pathway is modified according to the genotype.
Within the THOP1 pathway, the expression of
angiotensin-converting enzyme (ACE), which converts
angiotensin I to angiotensin II, a potent vasoconstrictor, is
affected in both wild type and transgenic animals. No
study has focused on the effect of vitamin D3
supplementation on ACE expression. However, it has been
observed that VDR knockout mice display an increased
production of ACE mRNA [68]. Interestingly, this metal-
loprotease is involved in Alzheimer’s disease since human
ACE increases degradation and cleavage of Aβ [69–72].
Another interesting result is the finding that a number
of DEGs relate to vascular processes. Angiogenesis is a
complex process that involves the activation and modifi-
cation of several signaling pathways within endothelial
cells. A key mediator of this process is VEGF. Patho-
logical angiogenesis is now considered as a key contribu-
tor to the development of AD. Substantial evidence
suggests that the neurodegenerative process can be
caused by cerebral hypoperfusion which induces reduced
oxygen, glucose and nutrient supply to the brain, and
damages the parenchymal cells and the blood–brain bar-
rier (BBB). BBB dysfunction promotes oxidative stress,
inflammation, paracellular permeability and dysregula-
tion of nitric oxide [73]. Several signaling pathways such
as VEGF signaling, tight junction signaling, nitric oxide
signaling in macrophages and eNos signaling are dis-
turbed by vitamin D3 treatment, especially in Tg mice.
Conversely, we observed a misexpression of Apoe
mRNA only in wild type supplemented animals. This
protein is associated to cardiovascular diseases as well
as Alzheimer’s disease [74]. No direct interaction be-
tween vitamin D3 and ApoE has been unveiled so far.
However, several studies indicate putative interplays.
For example, the VDR mRNA regulates the phosphoryl-
ation and production of STAT1 [75] which in turn is
involved in the expression of apoE mRNA [76]. Fur-
thermore, the vitamin D system interacts with IGF1
and Esr1 (see below), the latter upregulating Apoe
mRNA in rat primary culture of hippocampal neurons
[77]. On the other hand, ApoE ɛ4 alleles have been
associated with reduced memory function and higher
serum 25(OH)D concentrations [78].
Overall, the fact that a large number of vitamin D-
related genes are categorized as AD-related in both Wt
and Tg animals is intriguing. This is suggestive of a
close link between vitamin D signaling and AD-related
signaling, as has been proposed by researchers [25, 79].
Although we observed a positive effect of vitamin D3
treatment on the amount of amyloid plaques, we never
detected a misexpression of the endogenous App tran-
script in our transgenic or wild type animals. This
comes as a relative surprise since it has been reported
that either the cotransfection of VDR or a calcitriol
treatment reduces, in a dose dependent manner, APP
transcription in neuroblastoma cells [18]. It is hypoth-
esized that VDR interacts with SMAD3 [80], a tran-
scription factor known to regulate APP transcription
through TGF beta signaling [81]. However, our data
failed to confirm these findings. In wild type mice,
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vitamin D3 supplementation induces an under-expression
of Smad6, Tgfb1 and Tgfbr1 transcripts without affecting
App expression. In addition, no misexpression of these
four mRNAs is observed in transgenic animals. It is there-
fore likely that other intermediate molecules, such as
those described below, are involved in the reduction of
amyloid burden.
An unexpected regulation of oxytocin and arginine
vasopressin transcripts in the cortex
One very intriguing result is the mRNA regulation of a
number of hormones classically known to be present in
the pituitary axis. It is true that OXT and AVP, for in-
stance, act as both hormones and central neurotrans-
mitters. However, to our knowledge, the presence of
local regulation of gene expression in the hippocampus
or cortex for both these hormones has never been re-
ported before. Binding sites for both hormones have
been described in different central regions such as the
amygdala, septum and olfactory region [82]. However,
while AVP receptors have been reported within the
hippocampus no OXT receptor has been found in this
area [83]. Both neuropeptides regulate rodent, primate
and human social behaviors and stress responses [84].
AVP influences memory processes in the brain by facili-
tating memory consolidation and retrieval [85, 86]. Re-
garding its role in AD pathology, a significant decrease
in AVP concentration was found in the brain of AD pa-
tients while application of AVP improves learning and
memory in aged people and in rats having received Aβ
[87–90]. OXT regulates hippocampal synaptic plasticity
and improves hippocampal-dependent cognitive func-
tions [91–93]. The direct or indirect regulation of these
neuropeptides by vitamin D3 could have important im-
plications for a number of behavioral and cognitive
processes in both the normal and pathological brain.
Differential expression of these two genes (Oxt and
Avp) was then measured by qPCR. A significant in-
crease for both these genes was only confirmed in the
cortex, although the same tendency is observed in the
hippocampus. It appears that important inter-individual
variations are present among the tested mice, further
supporting the idea that vitamin D3 acts not only in a
space- and time-specific manner, but also in an
individual-specific way.
A putative role of insulin growth factor 1 and estrogen
receptor 1 as downstream regulators
Four other gene expressions were assessed with qPCR
and, once again, not all were validated in each brain
area analyzed. Lcn2 and Ptgs2 are both involved in in-
flammatory signaling processes and have been found to
contribute to amyloid response in AD [94, 95]. Esr1
and Igf1 induce signaling pathways known to be
affected in AD. Several interactions between the estro-
gen and vitamin D endocrine system have been de-
scribed so far. 1,25(OH)2D3 may play an important
role in estrogen biosynthesis suggested by the fact that
serum estrogen levels are decreased in VDR knock-out
mice as compared with wild-type mice [96]. The direct
action of vitamin D on estrogen signaling is also cell-
specific as demonstrated by the fact that 1,25-(OH)2D3
increases estrogen receptor (ER) expression in osteoblast-
like cells, while it exerts a negative effect on ER in MCF-7
human breast cancer cells [97, 98]. An alteration in ER
distribution in AD hippocampal neurons has been de-
scribed, and, more precisely, a shift in cellular localization
of these receptors inhibits the development of AD path-
ology [99, 100]. Collectively, investigations suggest that
levels of estrogen receptors play an important role in neu-
roprotection and against neuroinflammation-induced de-
generation in AD [101, 102]. ESR1 has also been shown to
interact directly with amyloid processing through non-
genomic signaling via activation of MAPK/ERK pathway
[103]. Recently, two potential negative VDREs have been
identified in the promoter region of Esr1 [104] suggesting
a direct transcriptional action of vitamin D/VDR on ER
leading to an altered estrogen signaling mechanism
important to both Wt and AD-like brains. A possible
mechanism by which ESR1 confers neuroprotective effects
in AD is through interaction with IGF1R. Both in vivo and
in vitro studies have revealed interaction between ERs and
IGF1R in the promotion of neuronal survival, synaptic
plasticity and against Aβ toxicity [105, 106]. Insulin sig-
naling is emerging as an important event in neurode-
generative processes and aging in general. However,
inconsistencies regarding the role of insulin-like signal-
ing and its association to AD have appeared. In rodents,
reduced insulin/IGF1 signaling slows aging and there-
fore prevents development of neurodegenerative dis-
eases [107] but normal aging is associated with
declining levels of IGF1 and administration of insulin
can improve cognitive function in AD patients [108,
109]. Regardless, in vivo evidence shows that AD-like
pathology is significantly delayed in IGF1R knock out
mouse models of AD [110, 111]. Potential crosstalks
between vitamin D and IGF1 signaling have been put
forward. VDR knock-out mice display decreased ex-
pression of Igf1, Igf1r and Nf- kb [112]. 1,25(OH)2D3
also regulates the expression of a well-known anti-
aging gene, Klotho (Kl), whose expression is modified
in the hippocampus of both Wt and Tg mice in our
study. Kl dysregulation is linked to modulation of Insu-
lin/IGF1 signaling pathways [113]. Taken together,
these results largely support both direct and indirect
action of vitamin D/VDR on ESR1 and IGF1 signaling
pathways in both Wt and 5XFAD mice, as a mechanism
to reduce brain aging processes.
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Convergent data on amyloid plaque load and divergent
results on astrogliosis
The bulk of our study focuses on describing the similar-
ities or differences induced by chronic vitamin D3 sup-
plementation at the transcriptomic level in Wt and Tg
animals at M9. Importantly, the altered gene expression
translates into a modification of functional outcomes.
We note a link between the action of vitamin D3 on
gene regulation in our model and its effect at the histo-
logical and behavioral levels. We show here that
5 months of vitamin D3 treatment restores learning and
memory performance in Tg animals in both the Y-maze
and RAWM but does not affect cognitive outcome in
Wt mice. This is accompanied by a decrease in the num-
ber of amyloid plaques, astrocytic reactivity and subtle
changes in microglial activation for Tg animals having
been fed a vitamin D3 diet. Several studies have shown
an improvement in memory and cognitive function in
different models of AD or aging following vitamin D2,
vitamin D3 or 1,25(OH)2D3 treatment. In their work,
Yu and colleagues used young AβPP transgenic mice
and found an amelioration of performance in the Morris
Water Maze (MWM) for animals under a high vitamin
D3 diet. These behavioral changes were accompanied by
a diminished Aβ load, along with an increase in astro-
cytic reactivity, NGF levels and decreased TNF-α in the
brain of treated mice. This study focused on a preventive
action of vitamin D3, which might explain some of the
differences observed when comparing their data to ours.
Specifically, the increase in astrocytic marker GFAP is
inconsistent with the diminished GFAP staining ob-
served in our study [26]. This discrepancy might reflect
the balance by which vitamin D3 exerts its effects ac-
cording to the pathological context and the time of de-
livery. An increase in GFAP expression is a hallmark of
reactive gliosis and is found in many neuropathological
conditions, including AD. The functional changes asso-
ciated to this increased expression however are not fully
understood. To study the functional outcomes of GFAP
dysregulation on the surrounding brain tissue and cells,
GFAP knock-outs (KO) have been generated and when
combined to brain injury models, studies suggest that
GFAP increase is associated to protective mechanisms
[114, 115]. When GFAP KO mice were crossed with a
mouse model for AD, the deposition of amyloid plaques
was accelerated. Furthermore, neuritic dystrophy was ex-
acerbated and the interaction of astrocytes with plaques
was decreased [116]. These observations lead to the con-
clusion that astrogliosis can be considered as a brain
defense mechanism attempting to prevent plaque forma-
tion and neuronal damage, and this would take place
during the onset of the disease. However, we cannot rule
out that, at the same time, gliosis affects the synaptic
and metabolic support functions of astrocytes [116, 117].
It is then probable that with age and repeated insults,
chronic astrocyte reactivity may become deleterious,
engaging the opposite effect of vitamin D3 on GFAP
expression when compared to a younger tissue. We and
others have shown that genes involved in glial reactivity
and inflammation are among the earliest affected during
disease pathogenesis in the 5xFAD model and that these
are correlated with cognitive impairment [4]. We show here
that vitamin D3 is able to act specifically on both astrocytic
and microglial activation at both the transcriptomic and
histological levels. In the AD brain, microglial activation is
the driving force for the elaboration of an inflammatory
cascade [118] and reports show an upregulation of VDR
mRNA in microglia stimulated by Aβ in vitro [119], indi-
cating that microglia found around amyloid plaques could
increase their responsiveness to vitamin D metabolites.
Microglia, unlike the other cells of the nervous system,
stems from the myeloid lineage and is considered the
macrophages of the brain. As discussed thoroughly here
and elsewhere, the vitamin D system displays potent anti-
inflammatory roles in immune cells and the increase in
microglial activity in the frontal cortex of 5xFAD mice re-
flects the capacity of vitamin D3 to balance the pro- and
anti-inflammatory cytokine production regulated by micro-
glia [118, 120]. In addition, this enhanced activation of
microglia at the proteomic level could also reflect increased
phagocytic activity of Aβ, a process demonstrated to be
promoted by vitamin D3 in the macrophages of AD pa-
tients [121, 122]. Once again, it appears that vitamin D3
acts on both nervous system and the immune system path-
ways to reduce alteration in neuronal metabolism and fur-
ther preserve cognitive outcomes.
An age- and concentration-dependent action on
cognition
The study by Yu and colleagues does not present the ef-
fect of vitamin D3 on cognitive functions in the Wt coun-
terpart, leaving no comparison possible [26]. Accordingly,
an 8 week treatment with intraperitoneal injections of
1,25(OH)2D3 in a different mouse model of AD restored
learning and memory deficits, assessed by the fear condi-
tioning paradigm, compared to vehicle-treated Tg mice
but did not affect cognitive performance in non-Tg ani-
mals [123]. Yet, another study, which tested a 7 months
vitamin D2 supplementation in another AD mouse model,
concluded that, in this case, vitamin D2 improved cogni-
tive performance more reliably in Wt mice rather than Tg
at M9 [124]. And when focusing solely on the implication
of vitamin D in normal aging and memory disabilities,
Latimer and colleagues showed that a high vitamin D3
diet (10,000 IU/Kg diet) lasting 5 to 6 months prevented
cognitive decline in aging rats. The study demonstrates a
causal relationship between enhanced learning and mem-
ory during aging with vitamin D3 status which is
Landel et al. Molecular Neurodegeneration  (2016) 11:22 Page 15 of 22
underlined by enhanced synaptic transmission due to gene
expression changes in the brain [30]. At approximately the
same time, Briones and Darwish performed subcutaneous
injections of 1,25(OH)2D3, for 21 days, to both young and
aged rats (6 and 20 months, respectively) and observed an
attenuation of cognitive impairment accompanied by en-
hanced brain energy metabolism, modulation of inflam-
matory and redox state in aged rats after treatment
compared to controls [125, 126]. Both these studies
underlie a role for vitamin D metabolite supplementation
in the preservation of cognitive function in “normal”
aging animals. The middle-age period is characterized
by the onset of subtle changes in cognitive performance
that might not be detected by the straightforward tests
that are the Y-maze and RAWM. It is probable that M9
is not old enough to detect memory decline in Wt ani-
mals or that tests aiming at detecting more subtle per-
formance changes in executive function or processing
speed would be required to allow analysis of vitamin
D3 treatment on cognitive performance in Wt aging
animals.
Conclusions
Classically, investigations into physiological processes
and neurodegenerative disease pathogenesis have moved
from the whole organism to the molecular level as the
advent of genome-wide microarrays and large-scale gen-
ome sequencing have become powerful tools for probing
physiological mechanisms. Vitamin D signaling is ideally
suited for genomic analysis as its main receptor VDR is
a direct regulator of gene transcription. However, al-
though transcriptomic technologies have evolved greatly,
there is still no consensus about an optimal way to
analyze transcriptomic data. This renders comparison
with other studies rather difficult, especially when plat-
form and data analysis programs differ. The growing
knowledge about epigenetic mechanisms at play in gene
regulation and its relevance to vitamin D action in the
brain could not be addressed in this study but needs
further investigation in future experimental designs. The
absence of a clear consensus motif for VDREs also
impedes the pinpointing of direct vitamin D targets.
Moreover, a 5-month supplementation entails that tran-
scriptional activation is not the only mechanism at play,
and that membrane-based actions of vitamin D and its
related metabolites are to be considered. The interac-
tions between the vitamin D system and other signaling
pathways are clearly as important as direct transcrip-
tional activation or repression of 1,25(OH)2D3 targets,
as shown in this study.
The aim of this study was to i) assess the potential
therapeutic benefit and the mechanisms of action of a
chronic vitamin D3 supplementation in an AD model
and ii) extract information about specific signaling
pathways affected by vitamin D3 in the nervous system.
Therefore, validating each DEG obtained by microarray
assay using qPCR or proteomic approaches was largely
beyond the scope of the study but this needs to be fur-
ther addressed, especially for those genes put forward as
key partners or downstream actors. It is important to
note that the discordant results observed between
microarray data and qPCR analysis might reflect the im-
portance of inter-individual variability in response to
vitamin D3 treatment but also the limitations for each
method used. Indeed, transcriptomic data are normal-
ized to global measures while qPCR results are obtained
in reference to one housekeeping gene. Concerning Igf1
mRNA quantification, it is also likely that putatively low
levels followed by further reduction in gene expression
is more error prone and reaches the limit of qPCR ana-
lysis. Moreover, as our study emphasizes the time-, back-
ground- and individual-specific action of vitamin D3 in
the brain, it is obvious that differential activity at the
transcriptomic level is operated between the cortex and
hippocampus. Additional analysis of our data would
allow for more precise deciphering of vitamin D3 impact
in each brain area known to be affected in AD. The
study was also designed using a female cohort, and it
would seem extremely relevant to repeat such experi-
ments in male animals. This could help contribute to
the ongoing debate about the relevance of gender differ-
ences in the pathogenesis of the disease. Especially since
estrogen signaling appears to play an important part in
the events observed here, along with the mRNA dysreg-
ulation of a certain number of hormones, we cannot
exclude a sex-impact to be considered in the way vita-
min D3 acts on brain cells.
Lastly, animal studies using vitamin D treatment in
AD models, including ours, show improvement in vari-
ous markers of the disease but interventional clinical tri-
als, to date, failed to show such effects. It is important to
bear in mind that animal models of AD do not recapitu-
late fully the complex physiopathology of the disease
and major differences in regulation by the vitamin D sig-
naling system are observed, according to the species
concerned [127], possibly further increasing the gap
between the results obtained from animal and human
studies. Moreover, we chose to place ourselves in a
therapeutic context, however, reproducing such a study
in a preventive manner would allow refining the analysis
of vitamin D3 action in a time-dependent manner.
Indeed, one major current problem concerning clinical
trials, using vitamin D as a protective agent against
cognitive decline and AD, is the time and dose for treat-
ment. When comparing our study to others, we high-
light the differences in functional outcomes depending
on the time of treatment, the dose or metabolite used.
As with clinical trials, there is a great need for additional
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work in rodents before deciphering the exact mecha-
nisms of action of vitamin D in the nervous system.
However, we feel confident that the present dataset is a
useful public resource which reflects the variety and
pleiotropy of vitamin D3 actions in the brain with par-
ticular emphasis on the crosstalk between vitamin D3
activated pathways and those affected in AD and should
allow future studies to further validate the use of vitamin
D3 as a potent therapeutic agent in AD.
Methods
Animals and experimental design
Female 5XFAD transgenic mice were used for this study.
These mice overexpress two transgenes bearing five muta-
tions linked to familial AD: human APP (Swedish muta-
tion K670N, M671L; Florida mutation I716V; London
mutation V717I) and human presenilin 1 (PSEN1 M146L,
L286V), under transcriptional control of the mouse Thy1
promoter. 5XFAD lines from the B6/SJL genetic back-
ground were maintained by crossing hemizygous trans-
genic mice with B6/SJL F1 breeders. These mice exhibit
AD-related symptoms earlier than other animal models
and amyloid deposition starts in the cortex and subiculum
at 2 months of age [2, 128]. Heterozygous 5XFAD trans-
genic animals and wild type (Wt) controls were obtained
after breeding of progenitors purchased from the Jackson
Laboratory. Newborn pups were genotyped by polymerase
chain reaction (PCR) of tail DNA biopsies in order to de-
tect the human PSEN1 gene as previously described [128].
Animals were weaned at 4 weeks of age and fed an
identical diet until M4. Mice were then allocated to dif-
ferent groups: Wt animals on a control diet (1000 IU/kg)
(n = 10), Wt animals on a vitamin D3 enriched diet
(7500 IU/kg) (n = 11), transgenic animals on a control diet
(n = 14) and transgenic animals fed with the vitamin D3
enriched diet (n = 16) (INRA, France). Mice were tested at
M4, M6 and M8 in the Y-maze, and at M8 in the 6-radial-
arm water maze before euthanasia at M9. Animal experi-
ments were approved by the Ethics Committee of the
Medical Faculty of Marseille and were carried out in ac-
cordance with the guidelines published in the European
Communities Council Directive of November 24, 1986
(86/609/EEC). All efforts were made to reduce animal suf-
fering and the number of mice needed for the study.
Behavioural testing
Y-maze
Spontaneous alternation in the Y-maze was tested accord-
ing to the following protocol: each mouse was placed in a
random arm of the symmetrical Y-maze and was allowed
to explore freely through the maze during an 8 min ses-
sion. The sequence and total number of arms entered was
recorded. Arm entry was considered complete when the
hind paws were completely in the arm. Experiments were
done blind with respect to the genotype and diet of the
mice. Washing with water and ethanol was performed
between each passage. Percentage of alternation was de-
termined as follows: number of triads containing entries
into all three arms/maximum possible alternations (total
number of arms entered – 2) x 100.
6-Radial arm water maze
The 6-RAWM is a hybrid of the Morris water maze and
a radial arm maze. The test allows assessment of spatial
and reference memory. The mouse version of this maze
uses a circular pool with six swim alleys (arms) radiating
out from an open central area with a hidden escape plat-
form submerged at the end of one goal arm. The overall
design of the study was adapted from Alamed and col-
laborators [129], using a 3-day protocol containing 12
sessions per day. Visual cues were displayed around the
room and the experimenter remained visible throughout
the training sessions. For this procedure the goal arm
differed between mice but was held constant for each
mouse during all trials with a different start arm on suc-
cessive trials. The first day of training comprised of al-
ternating between hidden and visible platform. During
the 12 trials of the second and third day, the platform
remained hidden and the mice were required to use the
visual cues to locate the goal arm. When a mouse en-
tered a wrong arm, which did not contain the platform,
an error was scored. At the end of the procedure, mice
were tested in the circular pool using a visible platform,
to ensure their visual abilities were satisfactory for inclu-
sion in the study.
Tissue isolation
Brain tissues were collected at M9, from all groups. Mice
were anesthetized with isoflurane before sacrifice and
brains isolated from each animal. The hippocampus and
neocortex from a half brain were dissected, snap-frozen
in liquid nitrogen and stored at -80 °C until use. The
other hemi-brain was placed in 4 % paraformaldehyde
during 6 days at 4 °C, for further immunohistological
processing.
Tissue processing and immunostaining
Coronal brain sections from hemi-brains previously col-
lected and fixed in 4 % paraformaldehyde were serially
generated using a cryostat and stored at -20 °C in six-well
plates containing a cryoprotectant (30 % glycerol; 30 %
ethylene glycol (Sigma Aldrich, Saint-Quentin Fallavier,
France) diluted in 0,05 M PBS phosphate buffered saline
(pH 7.4) until being processed for immunostaining.
After washing in PBS, floating sections were incubated,
during 1 h at room temperature (RT), with a blocking
buffer (3 % BSA, 0.1 % Triton X-100 in PBS pH 7.4)
and, overnight at 4 °C, with the following primary
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antibodies diluted in the blocking solution: rabbit poly-
clonal anti-GFAP (1/500, Dako France, Trappes, France),
mouse monoclonal anti-Aβ, 6E10 (1/300, Covance,
Eurogentec, Angers, France) and rabbit polyclonal anti-
IBA1 (1/200, Wako, Sobioda, Montbonnot-Saint-Martin,
France). Then, slices were rinsed in PBS and incubated
for 90 min at RT with cross-absorbed Alexafluor 488-
conjugated anti-rabbit or 594-conjugated anti-mouse
secondary antibodies (1/500, Life Technologies, Saint
Aubin, France) along with Hoechst blue (1/1000, Sigma
Aldrich) in dark conditions. After several washes in PBS,
slides were mounted with ProLong Gold Antifade reagent
(Life Technologies).
Microscopic analysis and quantification of gliosis and
amyloid plaques
Quantification of gliosis and amyloid plaques were per-
formed on 30 μm thick brain coronal sections co-
stained with either GFAP and 6E10 or IBA1 and 6E10
antibodies, at the frontal cortex, hippocampal and sen-
sory cortex levels. Images were acquired using an
inverted Axio Observer microscope (Zeiss, Jena, Germany)
equipped with DAPI, FITC and TRITC epifluorescence fil-
ters. Images of large brain sections were obtained using the
mosaic mode of the Axiovision software (Zeiss). For 6E10,
GFAP and IBA1 staining quantifications, ImageJ software
was used. The pictures were binarized to 16 bit black and
white images and a fixed intensity threshold was applied
for all images. Percentage of covered area by the fluores-
cent staining was calculated. Eight mice per group and
three sections per mouse at three different levels were
used.
RNA isolation
Total RNA was isolated from the snap-frozen hippo-
campi and cortices using RNeasy Mini kit (Qiagen,
Courtaboeuf, France), according to the manufacturer’s
instructions. RNA concentration was determined using a
Nanodrop 2000 spectrophotometer (Life Technologies
ThermoFisher Scientific, Villebon sur Yvette, France)
and RNA integrity assessed on an Agilent 2100 Bioana-
lyzer (Agilent Technologies, Les Ulis, France).
Microarray assay
RNA samples from three animals in each group were
pooled for microarray hybridization. Sample amplifica-
tion, labeling, and hybridization were performed in line
with the Agilent one-color microarray-base analysis
(low input quick amp labeling) protocol (Agilent Tech-
nologies). Briefly, total RNA was reverse-transcribed
into cDNA using the T7 promoter primer. The reac-
tion intending to synthesize cyanine-3-labeled cRNA
from cDNA was performed in a solution containing
dNTP mix, T7 RNA polymerase and cyanine 3-dCTP
and then incubated at 40 °C for 2 h. Labeled cRNA
was purified and fragmented before hybridization on
Agilent 8x60k Mouse Gene Expression Arrays (Agilent
Technologies), containing 62,975 oligonucleotide probes,
at 65 °C for 17 h. Raw microarray signals were scanned
and extracted using Agilent Feature Extraction Soft-
ware (Agilent Technologies). AgiND R package was
used for quality control and normalization. Quantile
methods and a background correction were applied for
data normalization. Microarray data are available in the
ArrayExpress database under accession number E-
MTAB-1937.
Microarray data analysis
Biological interpretation of the data was performed
using two different programs. The NIH DAVID tool
was used to obtain functional annotation clusters
related to the datasets of interest. Ingenuity Pathway
Analysis (IPA, Ingenuity Systems) was also used to
identify biological functions and upstream regulators
relevant to the lists of DEGs analyzed. The main criter-
ion to validate a differentially expressed gene was a fold
change over 1.5 or under -1.5 when considering expres-
sion values in the group supplemented with vitamin D3
relative to the control diet group, whether considering
wild type or transgenic animals. Upregulated and
downregulated genes were analyzed in the same data-
sets to obtain the biologically relevant function categor-
ies. Right-tailed Fisher’s exact test was used to calculate
a p-value determining the top statistically significant
biological functions assigned to the data set.
Real-time quantitative PCR (qPCR)
Total RNA (750 ng) was subjected to reverse transcrip-
tion reaction to synthetize cDNA using oligo dT, RNase
Out and M-MLV RT enzyme (Life Technologies, Ther-
moFisher Scientific) according to the manufacturer’s
instructions.
Real time qPCR experiments were carried out with the
7500 Fast real-Time PCR system (Applied Biosystems,
ThermoFisher Scientific), using TaqMan® Fast Universal
PCR Master Mix (2X) and the following TaqMan® Gene
Expression Assays: Oxt (Mm00726655_s1), Avp (Mm00
437761_g1), Lcn2 (Mm01324470_m1), Ptgs2 (Mm00478
374_m1), Esr1 (Mm00433149_m1), Igf1 (Mm004395
60_m1), Gapdh (Mm99999915_g1). Experiments used
7.5 ng of previously prepared cDNA and samples were run
in triplicates on six different biological samples for each
group. Relative expression levels were determined accord-
ing to the ΔΔCt method where the expression level of the
mRNA of interest is given by 2-ΔΔCT where ΔΔCT=ΔCT
target mRNA −ΔCT reference mRNA (Gapdh) in the
same sample as previously described [4, 128].
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Statistical analysis
Significant differences between groups were determined
using the Kaleida Graph software. We used one-way
ANOVA followed by a post-hoc Bonferroni test for mul-
tiple comparisons. Kruskal-Wallis test was used to com-
pare two experimental groups. Values represent the
mean ± SEM of the indicated number of independent ex-
periments/animals, and the level of significance was set
for p < 0.05 * or p < 0,01**.
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